Ousia Pharma ApS: Financial statements 2023
CVR: 43055909
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Ousia Pharma ApS (CVR 43055909) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -2,239,754 and a net result of DKK -3,746,803 compared with DKK -904,151 the year before. Equity in the 2023 report amounted to DKK -4,738,298. The company had 5 employees in the financial year.
- Gross Profit
- DKK -2,239,754
- Profit/Loss
- DKK -3,746,803
- Equity
- DKK -4,738,298
- Total Assets
- DKK 5,798,437
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -2.2 mio. | -3.7 mio. | -4.7 mio. | 5 |
| 2022 | - | -645 t. | -904 t. | -864 t. | 3 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Ousia Pharma ApS has published its interim report for the period February 14, 2022 – December 31, 2022.
As of February 14, 2023, Ian Rodney Laquian has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Mikael Søndergaard Thomsen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Jeppe Ragnar Andersen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Morten Peltola Toft has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Christoffer Clemmensen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Jonas Odgaard Petersen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Anders Bue Klein has joined the board of directors of Ousia Pharma ApS.
About Ousia Pharma ApS
Ousia Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ouisa Pharma ApS. The management consists of Anders Bue Klein, Christoffer Clemmensen and Jonas Odgaard Petersen. The board consists of Gaurav Gupta (chair), Menelas Nicolas Pangalos, Otello Stampacchia and Ramesh Rajanikant Bhatt. The company is owned by JLSa2 Therapeutics, Inc.. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK -10,204,929 and a net result of DKK -12,777,761 compared with DKK -5,348,579 the year before. Equity in the 2025 report amounted to DKK 11,818,220.